Phase I Study of Paclitaxel and Uracil plus Tegafur Combination in Patients with Pretreated Metastatic Breast Cancer: Drug Sequencing Based on Preclinical Modelling Studies
Authors:
- A. PassardiAPA. Passardi
- R. MaltoniRMR. Maltoni
- C. MilandriCMC. Milandri
- L. CecconettoLCL. Cecconetto
- I. MassaIMI. Massa
- W. ZoliWZW. Zoli
- A. TeseiATA. Tesei
- F. FabbriFFF. Fabbri
- O. NanniONO. Nanni
- D. AmadoriDAD. Amadori
- 1 November 2007
- journal article
- Published by S. Karger AG in Oncology
- Vol. 72 (1-2) , 118-124
Abstract
Objective: Taxanes and fluoropyrimidines are active in metastatic breast cancer (MBC), and their combination has proven effective in anthracycline-refractory patients. We conducted a phase I study to determine the maximum tolerated dose (MTD) of uracil plus tegafur (UFT) given in combination with leucovorin (LV) and paclitaxel (Pacl) in patients with refractory MBC. Methods: Pacl was infused at a fixed dose of 150 mg/m2 on day 1. UFT, at doses escalated by 50 mg/m2 starting from 200 mg/m2 · day, and LV, at a fixed dose of 90 mg/day, were given orally every 8 h for 11 days (days 3–13). Cohorts of at least 3 patients were treated at each dose level, and if 1 experienced dose-limiting toxicity (DLT), a maximum of 3 additional patients were added at the same dose level. MTD was reached if 2 out of the 6 patients experienced DLT. Results: Sixteen patients were enrolled in the study. The most important toxicity observed was hematological. Nonhematological toxicities were paresthesia and myalgia, asthenia, nausea, and mucositis. DLT occurred in only 1 patient (grade 3 hepatic toxicity). Conclusions: The recommended dose for a subsequent phase II trial is Pacl 150 mg/m2 on day 1, and UFT 300 mg/m2 and LV 90 mg on days 3–13, every 2 weeks.Keywords
This publication has 14 references indexed in Scilit:
- Weekly paclitaxel plus capecitabine in advanced breast cancer patients: dose-finding trial of GOIRC and GOLAnnals of Oncology, 2005
- Capecitabine Plus Paclitaxel As Front-Line Combination Therapy for Metastatic Breast Cancer: A Multicenter Phase II StudyJournal of Clinical Oncology, 2004
- Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancerBritish Journal of Cancer, 2004
- Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast CancerBreast Cancer Research and Treatment, 2003
- Taxanes for Breast Cancer: An Evidence-Based Review of Randomized Phase II and Phase III TrialsClinical Breast Cancer, 2000
- Cyclophosphamide, methotrexate, and chronic oral tegafur modulated by folinic acid in the treatment of patients with advanced breast carcinomaCancer, 1998
- A Comparative, Randomized Trial of UFT® and 5-Fluorouracil in Combination with Cyclophosphamide and Doxorubicin in the Treatment of Advanced Breast Cancer Patients at The Philippines General HospitalOncology, 1997
- Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancerCancer, 1995
- Oral tegafur in the treatment of metastatic breast cancer: A phase II studyEuropean Journal of Cancer, 1993
- Chemotherapy of breast cancer: Current views and resultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1983